Tuesday, 24 October 2017
Meeting category
Date(s)
24 Oct 2017
Location
Milan,
Italy
Organizer
European HIV Clinical Forum 2017
Related Enduring Materials
Enduring Materials
Session I -
State of the ART: Integrase Inhibitors Resistance
State of the ART: Integrase Inhibitors (clinical overview) (not available)
Session II -
What is the virological support for reduced drug regimens?
What is the clinical support for reduced drug regimens?
Can we use HIV reservoir assays to predict VF in simplification strategies? (not available)
Session III -
Oral abstract presentation
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy as a Switching Regimen in HIV-TR Cohort.
Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.
French national survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 Virology Network).
In-vitro selection of resistance mutations to dolutegravir outside HIV-1 integrase.
Changes outside integrase in a patient failing on dolutegravir maintenance monotherapy points to a new resistance mechanism. (not available)
C. Lungu
The Netherlands
Genetic variability of HIV-2 LTR regions impacts transcriptional activities.
Serum cystatine as a marker for estimated glomerular filtration rate (eGFR) assessment in HIV-1-infected patients with dolutegravir-based antiretroviral therapy (ART).
Evolution of bone mineral density and MDRD in HIV-infected patients treated with dolutegravir based regimens: results at 48- weeks
Clinical case presentation
Session IV -
One pill a day?: Integration novel delivery systems into routine care
Overview
Welcome
The European HIV Clinical Forum 2017 was held on 24 October 2017 in Milan, Italy, preceding the EACS 2017.
The meeting was a great success with almost 100 attendees visiting the meeting!
The European HIV Clinical Forum focused entirely on Integrase Inhibitors as Integrase Inhibitors are rapidly gaining a central role in the routine care of HIV infected individuals. The HIV Clinical Forum meetings aim at enhancing the clinical skills and research capabilities of HIV healthcare professionals in regard to this unique class of antiretroviral drugs.
On behalf of the European HIV Clinical Forum Program Chairs, we would like to thank ViiV Healthcare for their unrestricted education grant, as well as Mylan for their generous contribution. We would also like to thank our endorsers for their invaluable support of the meeting and of course a big thank you to all of our participants.
Program Chairs
Jonathan Schapiro, MD
National Hemophilia Center Sheba Medical Center, Israel
Charles Boucher MD, PhD
Medical Center, The Netherlands
Local Chair
Marcel Stöckle, MD
University Hospital Basel, Switzerland
General Information
Meeting Objectives
With the HIV Clinical Forum program we aim to:
- Build a community of healthcare professionals devoted to providing optimal clinical care for their patients
- Create a platform for interactive information exchange on novel treatment options
- Translate the latest research achievements into clinical guidance for the optimal management of HIV-positive individuals
- Build a community of healthcare professionals devoted to providing optimal clinical care for their patients
- Create a platform for interactive information exchange on novel treatment options
- Translate the latest research achievements into clinical guidance for the optimal management of HIV-positive individuals
Learning Objectives
After participating in the HIV Clinical Forum, participants will be able to:
- Understand the clinical data supporting novel treatment strategies
- Describe the pros and cons of novel treatment strategies
- Understand how to integrate novel treatment strategies into routine patient care
- Be knowledgeable of the clinical data supporting long-acting injectable regimens
- Identify patients who might best benefit from long acting injectable regimens
- Know how best to integrate injectable drugs in to routine clinical care
- Understand the clinical data supporting novel treatment strategies
- Describe the pros and cons of novel treatment strategies
- Understand how to integrate novel treatment strategies into routine patient care
- Be knowledgeable of the clinical data supporting long-acting injectable regimens
- Identify patients who might best benefit from long acting injectable regimens
- Know how best to integrate injectable drugs in to routine clinical care
Language
